← Leaderboards
Can Martin Zhang
Massachusetts General Hospital
$10,046,963
Attributed
$19,181,956
Total exposure
14
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.3M · FY2011–25$5M$3.8M$2.5M$1.3M$0
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$19,181,956 · 14
By mechanism
R01$7,802,182 · 5
RF1$4,181,352 · 2
R61$4,131,086 · 2
R56$823,571 · 1
R33$791,560 · 1
R00$739,529 · 1
Top collaborators
- Changning Wang13 shared
- Juejun Hu4 shared
- Fenglong Ma4 shared
- Shiqian Shen4 shared
- Chongzhao Ran2 shared
- Timothy T Houle1 shared
- Xingjie Ni1 shared
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Changning Wang$11,415,964
- Boris Dominik Juelg$12,991,342
- Jolan Eszter Walter$2,915,657
- Robert L Martuza$21,256,149
- Fotis Constantine Kafatos$1,485,257
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposS DiseaseNeurodegenerative DisordersDementiaBrainElderlyNeuronsPathogenesisBaseMouse ModelReportingBindingDesignAnimalsGrantCell ModelLeadClinical TrialsPropertyAmyloid Beta-ProteinDoseGeneticInsightCells
Grant awards (30)
Molecular Chemiluminescence Probes for Imaging of Amyloid beta in Animal Models$808,786
R01 · FY2025 · AG
Molecular imaging of RIPK1/necroptosis as a key biomarker in Alzheimer's disease$791,560
R33 · FY2025 · AG
New epigenetic inhibitors for Alzheimer's disease treatment$790,816
R01 · FY2025 · AG
Gut Microbiota Underlies the Heterogeneity of Aging Brain's Susceptibility to Postoperative Delirium$622,824
R01 · FY2025 · AG
SCH: AI-Enhanced Multimodal Sensor-on-a-chip for Alzheimer's Disease Detection$281,226
R01 · FY2025 · AG
Molecular Chemiluminescence Probes for Imaging of Amyloid beta in Animal Models$823,551
R01 · FY2024 · AG
New epigenetic inhibitors for Alzheimer's disease treatment$806,956
R01 · FY2024 · AG
Gut Microbiota Underlies the Heterogeneity of Aging Brain's Susceptibility to Postoperative Delirium$648,974
R01 · FY2024 · AG
SCH: AI-Enhanced Multimodal Sensor-on-a-chip for Alzheimer's Disease Detection$292,449
R01 · FY2024 · AG
BET-BD1 Selective Neuroimaging probes for Alzheimer's disease research$2,442,345
RF1 · FY2023 · AG
SCH: AI-Enhanced Multimodal Sensor-on-a-chip for Alzheimer's Disease Detection$297,698
R01 · FY2023 · AG
Inhibiting RIPK1 with Necrostatin-1 for Safe and Effective Pain Treatment$1,633,790
R61 · FY2022 · NS
Molecular imaging of RIPK1/necroptosis as a key biomarker in Alzheimer's disease$832,432
R61 · FY2022 · AG
Characterizing the roles of novel soluble GSMs in AD pathology.$425,945
R01 · FY2022 · AG · contact PI
SCH: AI-Enhanced Multimodal Sensor-on-a-chip for Alzheimer's Disease Detection$299,177
R01 · FY2022 · AG
Gut Microbiota Underlies the Heterogeneity of Aging Brain's Susceptibility to Postoperative Delirium$1,739,007
RF1 · FY2021 · AG
Molecular imaging of RIPK1/necroptosis as a key biomarker in Alzheimer's disease$832,432
R61 · FY2021 · AG
Characterizing the roles of novel soluble GSMs in AD pathology.$425,945
R01 · FY2021 · AG · contact PI
Molecular imaging of RIPK1/necroptosis as a key biomarker in Alzheimer's disease$832,432
R61 · FY2020 · AG
Characterizing the roles of novel soluble GSMs in AD pathology.$425,945
R01 · FY2020 · AG · contact PI
Molecular imaging of PS1/gamma-secretase and analysis of Alzheimer's disease.$208,640
R21 · FY2020 · AG · contact PI
Characterizing the roles of novel soluble GSMs in AD pathology.$425,945
R01 · FY2019 · AG · contact PI
Molecular imaging of PS1/gamma-secretase and analysis of Alzheimer's disease.$250,640
R21 · FY2019 · AG · contact PI
Optogenetic modulation and pathophysiological analysis of Alzheimer's disease.$823,571
R56 · FY2018 · AG · contact PI
Characterizing the roles of novel soluble GSMs in AD pathology.$425,945
R01 · FY2018 · AG · contact PI
Characterization of ATXN1 in APP processing and AD pathogenesis$249,000
R00 · FY2016 · AG · contact PI
Characterization of ATXN1 in APP processing and AD pathogenesis$241,529
R00 · FY2015 · AG · contact PI
Characterization of ATXN1 in APP processing and AD pathogenesis$249,000
R00 · FY2014 · AG · contact PI
Characterization of ATXN1 in APP processing and AD pathogenesis$126,698
K99 · FY2012 · AG · contact PI
Characterization of ATXN1 in APP processing and AD pathogenesis$126,698
K99 · FY2011 · AG · contact PI